INTRODUCTION
Primary open-angle glaucoma (POAG) is a chronic, progressive, optic neuropathy involving retinal ganglion cell death and optic nerve degeneration.
Although a number of risk factors are associated with the development of POAG, including family history, age, race, intraocular pressure (IOP), and use of topical or systemic corticosteroids, the reduction of IOP is the only proven method of treatment for the disease [1, 2] . Normal tension glaucoma (NTG) is defined as POAG with an IOP of B21 mmHg, and accounts for a significant proportion of POAG cases, particularly in the Asian population [3, 4] . The Collaborative Normal Tension Glaucoma Study demonstrated that, despite being within the normal range, IOP is a factor in the optic nerve damage observed in NTG and that therapy aimed at lowering IOP is beneficial in patients at risk of progression [5, 6] . Latanoprost acid, the active moiety present in Xalatan Ò (latanoprost ophthalmic solution 0.005%), lowers IOP through a mechanism that mainly involves long-term remodeling of the extracellular matrices in the ciliary body, thereby increasing uveoscleral (nonconventional) aqueous humor outflow [11] [12] [13] [14] [15] . Nitric oxide is an endogenous signaling mediator which has been shown to lower IOP in clinical and animal models of OHT [16] [17] [18] [19] [20] [21] and has been implicated in IOP homeostasis in POAG patients [22, 23] 
Subjects
Subjects who participated in this study were recruited from a pool of healthy volunteers. All subjects were required to be male, at least 20 years of age, and be able to self-administer eye drops. A normal ophthalmic history and corrected decimal visual acuity (VA) of 0.5 or better in both eyes were also required for study enrollment. Subjects were not allowed to use non-prescription (including vitamins or dietary supplements) or prescription drugs 28 days prior to study drug administration or during the study treatment period (14 days).
Additionally, subjects were excluded from the study if they had a history of severe ocular trauma or incisional surgery, a history of ocular laser surgery (90 days), or had any intraocular inflammation or infection within 90 days prior to screening.
Study Treatments and Assessments
All subjects instilled LBN ophthalmic solution 0.024% (manufactured by Bausch & Lomb Inc, Tampa, FL) QD for 14 days at approximately 8 PM, starting on the evening of day 1 and ending on the evening of day 14, and completed three study visits (Fig. 1 ). Visit 1, the screening visit, occurred from 1 to 28 days prior to Visit 2, the baseline visit. At the screening visit, subjects were evaluated against the inclusion and exclusion criteria and, if found to be suitable for enrollment, vital signs, corrected decimal VA, a slit-lamp examination, IOP measurements, and ophthalmoscopy assessments were conducted. A urine sample for drug testing and a blood sample for serology testing were also collected. At screening and at all study visits, IOP was determined in both eyes using Goldmann applanation tonometry in the sitting position.
Adverse events were collected at all study visits. 
Statistical Methods
The intent-to-treat (ITT) population included all subjects who received at least one dose of study drug and had at least one post-baseline IOP assessment. The safety population included all subjects who received at least one dose of study 12 PM, 4 PM) for each subject's eyes (study eye and fellow eye, separately) and determining the mean (SD) of those. All statistical analyses were conducted using SAS version 9.1 (SAS Institute, Inc., Cary NC).
Adverse events (AEs) were summarized using discrete summaries at the subject and event level by system organ class and preferred term.
Ophthalmoscopy and slit-lamp examination measurements were summarized using descriptive statistics for discrete variables.
Visual acuity was summarized using descriptive statistics for continuous variables.
Dosing compliance was assessed based on returned subject diaries using the following calculation:
Percent compliance = 100 Â ½ number of instillations received= date of diary ½ collection -date of first dose + 1:
RESULTS

Subject Disposition and Demographics
A total of 45 subjects were screened and 24 subjects were enrolled in the study. All enrolled subjects completed the assessments required for the three study visits. There were no major protocol violations; hence the ITT and PP populations were the same. The mean (SD) age of the study subjects was 26.8 (6.3) years (range 20-39 years). All subjects were male, as specified by the study inclusion criteria. Mean (SD) 24-h baseline IOP was 13.6 (1.3) mmHg in the study eye and 13.9 (1.3) mmHg in the fellow eye.
All subjects were 81-120% compliant with dosing instructions based on the information recorded in the subject diaries. Twenty-two subjects administered all 14 daily doses and two subjects administered 13 out of 14 daily doses.
Efficacy Results
The 
Safety Results
No serious adverse events were reported during the course of the study. A total of 55 ocular and one non-ocular treatment-emergent adverse events (TEAEs) were reported. One subject reported the occurrence of a non-ocular TEAE during the study (mild upper respiratory inflammation) that was considered unrelated to study treatment. The 55 ocular TEAEs occurred in 22 subjects (28 associated with the study eye; 27 associated with the treated fellow eye), and were all determined to be mild; the majority of ocular TEAEs were judged to be at least possibly or probably related to the study drug treatment [study eye 96.4% (27/28), fellow eye 96.3% (26/27)]. Punctate keratitis and conjunctival hyperemia were the most commonly reported adverse events (Table 1 ).
There were no meaningful changes in vital signs or VA from screening to Visit 3. Mean (SD) Fig. 2 Mean intraocular pressure (IOP) over 24 h at baseline and after 2 weeks of treatment with latanoprostene bunod, 0.024% in the study eye (a), and the treated fellow eye (b) Fig. 3 Change from baseline in mean intraocular pressure (IOP) over 24 h after 2 weeks of treatment with latanoprostene bunod, 0.024%. The mean change from baseline (CFB) ± standard error (mmHg) for the study eye and the treated fellow eye are depicted. Statistically significant differences were observed at all measured time points over the 24-h monitoring period for the CFB in mean IOP assessments in both eyes (P\0.0001; paired t test) systolic/diastolic blood pressure was 111.1 (10.7)/66.9 (9.7) at baseline and 103.9 (10.2)/ 61.3 (9.8) post-treatment; mean heart rate was 64.9 (9.7) beats per minute (bpm) at baseline and 65. 
